Regeneron Pharmaceuticals Inc (REGN)vsTarsus Pharmaceuticals Inc (TARS)
REGN
Regeneron Pharmaceuticals Inc
$749.47
+1.05%
HEALTHCARE · Cap: $78.41B
TARS
Tarsus Pharmaceuticals Inc
$66.96
+6.03%
HEALTHCARE · Cap: $2.69B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 3078% more annual revenue ($14.34B vs $451.36M). REGN leads profitability with a 31.4% profit margin vs -14.7%. REGN earns a higher WallStSmart Score of 58/100 (C).
REGN
Buy58
out of 100
Grade: C
TARS
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Intrinsic value data unavailable for TARS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Revenue surging 128.4% year-over-year
Areas to Watch
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
Trading at 8.3x book value
0.0% earnings growth
ROE of -23.4% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bull Case : TARS
The strongest argument for TARS centers on Revenue Growth. Revenue growth of 128.4% demonstrates continued momentum.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : TARS
The primary concerns for TARS are Price/Book, EPS Growth, Return on Equity.
Key Dynamics to Monitor
REGN profiles as a value stock while TARS is a hypergrowth play — different risk/reward profiles.
TARS carries more volatility with a beta of 0.60 — expect wider price swings.
TARS is growing revenue faster at 128.4% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (58/100 vs 32/100), backed by strong 31.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Tarsus Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions. The company is headquartered in Irvine, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?